Novartis Announces Positive Phase III Results for Remibrutinib in Relapsing Multiple Sclerosis

Novartis has reported positive topline results from its Phase III REMODEL-1/-2 trials for remibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, in adults with relapsing multiple sclerosis (RMS). The trials demonstrated remibrutinib's superiority over teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, along with a favorable safety profile. This establishes remibrutinib as a significant development for RMS treatment.